Luminex Raises $83 Mil In Public Stock Offering

Multiplex testing technology finds ready acceptance with diagnostics & drug firms

CEO SUMMARY: During the past year, Luminex Corporation moved swiftly to push its LabMAP™ multiplex testing technology into the bioassay marketplace. It found high interest among companies in the pharmaceutical, diagnostics, and bioresearch industries. Luminex executives say that a number of companies are working to have FDA-approved diagnostic test kits available for laboratories by year’s

Subscriber-Only Content. Please Log In.

You are trying to access subscribers-only content. If you are a subscriber, please log in.

If you are not a subscriber, click here to see subscription offers.

Subscribers will have instant access to the Dark Report library, 1997-the present, giving you the most convenient, accessible archive available in laboratory business intelligence today!

To read our FREE article previews, go to The Dark Report Insider.

Tags: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , ,

Enter Your Login Credentials
×